Solifenacin
- Generic Name
- Solifenacin
- Brand Names
- Vesicare
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N2O2
- CAS Number
- 242478-37-1
- Unique Ingredient Identifier
- A8910SQJ1U
- Background
Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily.
Solifenacin was granted FDA approval on 19 November 2004.
- Indication
Solifenacin tablets are indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse
- Conditions
- Interventions
- First Posted Date
- 2010-03-25
- Last Posted Date
- 2011-11-04
- Lead Sponsor
- Hartford Hospital
- Target Recruit Count
- 94
- Registration Number
- NCT01092624
- Locations
- 🇺🇸
Hartford Hospital, Hartford, Connecticut, United States
Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters
- Conditions
- Interventions
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2012-06-08
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 56
- Registration Number
- NCT01028014
- Locations
- 🇺🇸
University of Alabama at Birmingham, The Kirklin Clinic, Birmingham, Alabama, United States
Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients
- First Posted Date
- 2009-09-28
- Last Posted Date
- 2011-10-12
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1215
- Registration Number
- NCT00985387
Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency
- Conditions
- Interventions
- First Posted Date
- 2009-09-18
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 291
- Registration Number
- NCT00979472
Validation of a Real-time Urodynamic Measure of Urinary Urgency
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- Loyola University
- Target Recruit Count
- 51
- Registration Number
- NCT00909428
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- KYU-SUNG LEE
- Target Recruit Count
- 307
- Registration Number
- NCT00884104
Over Active Bladder Patients Having Sling Surgery
- First Posted Date
- 2009-02-27
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Cleveland Clinic Florida
- Target Recruit Count
- 1
- Registration Number
- NCT00852696
- Locations
- 🇺🇸
Cleveland Clinic Florida, Weston, Florida, United States
Multiple Dose Study To Investigate The Effects Of Fesoterodine And Solifenacin On Gastrointestinal Transit
- Conditions
- Interventions
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2010-12-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 60
- Registration Number
- NCT00832650
- Locations
- 🇺🇸
Pfizer Investigational Site, Rochester, Minnesota, United States
Solifenacin Succinate Versus Tolterodine 4mg Once Daily
- Conditions
- Interventions
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1355
- Registration Number
- NCT00802373
Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms
- Conditions
- Interventions
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 973
- Registration Number
- NCT00801944
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.